Lukas Biomedical Inc.

NT$17.90As of Sun 8 Nov 2026, 12:00 UTC
TPEx:6814Healthcare
Country Taiwan
PE (Fwd) •••
TSR 6Y CAGR (17.12%)
Div yield —
ROE (38.79%)
Biotechnology
Beta (5Y) 0.09
PE TTM —
TSR TTM (36.30%)
Mkt cap NT$749.6M
ROIC (12.65%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$19
8.41%
(55.12%)
Hold 11|5|1|0|10
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.38
0.36
0.38
0.41
1.23%
(1.05%)
(2.33%)
4.09%
RevenueNT$M
65.62
66.85
68.39
72.02
0.23%
2.20%
5.75%
9.35%
Peers (US$22.77M)
Cap (US$)
PE
21.97M
17.86x
22.69M
—
Capital
TTM
5Y
10Y
Leveragex
2.642
0.469
0.401
EBIT/Intx
0.968
0.481
0.387
Own earn%
36.18
(29.46)
(23.17)
Sh yield%
27.53
55.33
55.10
Owners
Insiders/Inst%
9.50
86.64
Short interest%
2.27
SBC / revenue%
1.45
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
7
Op margin range%
10–15
$1 testx
0.3
Incr. ROIC%
5